The Market Reports

Synopsis

The global market for Ursodeoxycholic Acid API was estimated to be worth US$ 583 million in 2024 and is forecast to a readjusted size of US$ 995 million by 2031 with a CAGR of 8.7% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Ursodeoxycholic Acid API cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Ursodeoxycholic Acid is also known as ursodiol (USAN). Ursodeoxycholic acid (3α, 7β-2-hydroxy-5β-bile acid, UDCA) was first found in the bile of a black bear. Ursodeoxycholic Acid is an important clinical drug in the treatment of gallstones, cholecystitis, PBC, and PSC and has broad market prospects. In previous work, ursodeoxycholic acid was prepared by traditional organic synthesis. In this report, the Ursodeoxycholic Acid we mentioned is Ursodeoxycholic Acid API. In addition, the CAS number is 128-13-2.

The growing prevalence of liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and certain forms of liver cirrhosis, serves as a significant driver for the Ursodeoxycholic Acid (UDCA) API market. As more individuals are diagnosed with these conditions due to improved medical awareness and diagnostic techniques, the demand for effective treatments like UDCA increases. UDCA has demonstrated efficacy in managing and alleviating symptoms of these liver diseases, positioning it as a valuable therapeutic option. The rising global burden of liver disorders, often associated with factors like aging and lifestyle changes, provides a sustained demand for UDCA API as a key component in manufacturing medications to address these conditions.

However, the UDCA API market faces several challenges, with regulatory hurdles and price pressures being significant constraints. The stringent approval requirements and the need for high-quality production standards in API manufacturing can delay the market entry of new players and increase operational costs. Furthermore, with the increasing production of generic UDCA products, competition has intensified, leading to a decrease in profit margins for manufacturers of branded UDCA drugs. Another challenge is the limited scope of UDCA applications, as the drug is effective primarily for a specific set of liver conditions, limiting its broader market appeal. Additionally, supply chain disruptions and raw material price fluctuations for manufacturing UDCA can affect the availability and cost-effectiveness of APIs, further complicating market dynamics.

Global key players of Ursodeoxycholic Acid API include ICE, Daewoong Chemical, PharmaZell GmbH and Zhongshan Bailing, etc. The top five players hold a share about 81%.

This report aims to provide a comprehensive presentation of the global market for Ursodeoxycholic Acid API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Ursodeoxycholic Acid API by region & country, by Type, and by Application.

The Ursodeoxycholic Acid API market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ursodeoxycholic Acid API.

Market Segmentation
By Company

• ICE
• Zhongshan Bailing
• Daewoong Chemical
• PharmaZell GmbH
• Dipharma Francis
• Suzhou Tianlv
• Sichuan Xieli
• Chuanning Bio
• Shilpa medicare
• Symbio generics
• Arch Pharma

Segment by Type

• Chemical Method
• Enzyme Method

Segment by Application

• Tablets
• Capsules
• Suspensions

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.